SARS-CoV-2

[Scientific Reports] Scientists reported that imatinib, an Abl tyrosine kinase inhibitor, robustly decreased SARS-CoV-2 infection and uncovered a mechanism of action.

[Heliyon] Investigators identified and ranked clinical and immunological features associated with progression to severe COVID-19 in order to investigate an immunological signature of severe disease.

[Signal Transduction and Targeted Therapy] Scientists demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and variants of concern, including B.1.617.2 variant, in vitro and in vivo.

[Nature Immunology] The authors utilize major histocompatibility complex multimers with single-cell RNA sequencing to profile SARS-CoV-2-responsive T cells ex vivo from humans with one, two or three antigen exposures, including vaccination, primary infection and breakthrough infection.

[Science Translational Medicine] Researchers measured neutralization of the Omicron BA.1 variant pseudovirus by post-vaccination serum samples after two and three immunizations with the Pfizer/BioNTech162b2 SARS-CoV-2 mRNA vaccine, convalescent serum samples from unvaccinated individuals infected by different variants, and clinical-stage therapeutic antibodies.

[Clinical infectious Diseases] Researchers investigated SARS-CoV-2 vaccine immunogenicity in PLWH according to current CD4 T-cell count.